Rashmi B. Halker Singh, M.D.

Closed for Enrollment

• A Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel Group, Multi-Dose Study Comparing the Efficacy and Safety of Subcutaneous LBR-101 with Placebo for the Preventive Treatment of Chronic Migraine Scottsdale/Phoenix, Ariz.

  The purpose of the study is to determine whether monthly subcutaneous administration of LBR-101 is safe and provides migraine prevention in patients with chronic migraine.

• A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Study Comparing the Efficacy and Safety of Two Doses of Subcutaneous LBR-101 with Placebo for the Preventive Treatment of High Frequency Episodic Migraine Scottsdale/Phoenix, Ariz.

  The purpose of this study is to determine whether monthly subcutaneous administration of LBR-101 is safe and provides migraine prevention in subjects with high frequency episodic migraine.

• A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura Scottsdale/Phoenix, Ariz.

  This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.

• A Non-Invasive Neuromodulation Device for Prevention of Episodic Migraine Headache Scottsdale/Phoenix, Ariz.

  This study will assess the efficacy of a neuromodulation device for the treatment of episodic migraine headache.

• A Parallel Group, Double-Blind, Randomized, Placebo Controlled Phase 3 Trial to Evaluate the Efficacy and Safety of ALD403 Administered Intravenously in Patients With Chronic Migraine (PROMISE 2) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess the efficacy and safety of ALD403 in the prevention of migraine headache in chronic migraineurs.

• A Parallel Group, Double-Blind, Randomized, Placebo Controlled, Dose-Ranging Phase 2 Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of ALD403 Administered Intravenously in Patients With Chronic Migraine Scottsdale/Phoenix, Ariz.

  The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.

• A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 With a Long-Term Open-Label Extension in Patients With Chronic Cluster Headache Scottsdale/Phoenix, Ariz.

  The main purpose of this study is to evaluate the efficacy of the study drug known as LY2951742 in participants with chronic cluster headache.

• A Phase 3, Multicenter, Randomized, Double-Blind, Placebo Controlled Single Attack Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine Scottsdale/Phoenix, Ariz.

  This study will evaluate the efficacy, safety, and tolerability of 2 doses of ubrogepant (25 and 50 mg) compared to placebo for the acute treatment of a single migraine attack.

• A Phase 3b Multicenter, Single-Arm, Open-Label Safety Study of LY2951742 (Galcanezumab) in Patients With Episodic or Chronic Cluster Headache Scottsdale/Phoenix, Ariz.

  The main purpose of this study is to assess the long-term safety and tolerability of galcanezumab administered up to once monthly in participants with episodic or chronic cluster headache who have completed study I5Q-MC-CGAL (NCT02397473) or study I5Q-MC-CGAM (NCT02438826).

• Erenumab For Treatment of Hemicrania Continua Scottsdale/Phoenix, Ariz.

  The purposes of this study are to evaluate the response of hemicrania continua to treatment with erenumab, and to evaluate the safety and tolerability of erenumab in patients with hemicrania continua.

• Individualized Prediction of Migraine Attacks Using a Mobile Phone App (Migraine Alert) Scottsdale/Phoenix, Ariz.

  The purpose of this study is to investigate the accuracy of predicting migraine attacks in individual patients using a mobile phone app and a Fitbit  to collect daily headache diary data, exposure/trigger data and physiologic data. It is believed the data will predict the occurrence of migraine attacks with high accuracy via the mobile phone app.

• Spectacle Tints and Thin-Films to Reduce Headache Frequency in Patients with Chronic Migraine Scottsdale/Phoenix, Ariz.

  The purpose of this study is to compare eye glass lenses that have been treated with tints, to lenses that have been treated with thin-films to reduce light sensitivity and headache in patients who have chronic migraine. It is unknown if there is an advantage to either spectacle lens treatment. Both treatments could be a novel, non-invasive addition in the treatment of chronic migraine.

• Sphenopalatine Ganglion Stimulation for the Treatment of Chronic Cluster Headache (Pathway CH‐2) Scottsdale/Phoenix, Ariz.

  The primary objective of the study is to demonstrate the safety and efficacy of SPG stimulation with the ATI Neurostimulation System when used to treat acute cluster attacks in chronic cluster headache patients.